Bacterial Vaginosis: Symptoms, Testing, Treatment, and Recurrence

Direct answer: Bacterial vaginosis, or BV, is a change in the vaginal bacterial community, not proof of poor hygiene or infidelity. It may cause thin discharge and a fishy odour, but many people have no symptoms and symptoms alone cannot confirm it. Diagnosis may use clinical criteria, microscopy or a validated molecular test. Clinician-selected antibiotics treat symptomatic BV; recurrence is common, and prevention and partner strategies need individualized, up-to-date discussion. [1] [2] [3] [4] [5] [6]

Key takeaways

• BV is vaginal dysbiosis, meaning a shift from the usual bacterial community toward a more diverse group of anaerobic bacteria. It is not simply “too much Gardnerella,” and it is not classified as an STI. [1] [2]
• Thin white or grey discharge and fishy odour can occur, often after sex or around menstruation, but BV can also be symptom-free. Odour, colour and home pH cannot diagnose it. [1] [2] [3] [4] [5]
• Yeast infection more often causes marked itch and soreness with thick discharge, while trichomoniasis and cervicitis may overlap with BV. Testing matters when the diagnosis is uncertain, symptoms recur, pregnancy is involved or STI exposure is possible. [1] [4] [5]
• Current guideline options include oral or vaginal metronidazole and vaginal clindamycin. These are examples for clinician-led selection, not personal prescriptions. [1] [6]
• The CDC no longer recommends a blanket alcohol ban with metronidazole because convincing evidence of a disulfiram-like reaction is lacking. Follow the exact product label and prescriber’s advice, and do not assume the same advice applies to tinidazole. [1]
• Recurrent BV is frustrating but common. Suppressive regimens, selected adjuncts and partner treatment are evolving areas. Boric acid requires strict safety precautions, and retail probiotics should not be equated with trial-specific live biotherapeutics. [1] [7] [8] [9] [10] [11] [12] [13]

What is bacterial vaginosis?

Bacterial vaginosis is a vaginal dysbiosis. In plain language, the balance and structure of the vaginal bacterial community has shifted. BV often involves fewer lactic-acid-producing Lactobacillus bacteria and greater numbers of varied anaerobes, with a biofilm attached to vaginal cells. Gardnerella species may be part of that community, but finding one organism does not by itself define the condition. [1] [2] [7]

The label “vaginosis” reflects that BV usually causes less obvious inflammation than some forms of vaginitis. That does not mean symptoms are imaginary or harmless. BV is associated with increased susceptibility to several STIs and with reproductive and pregnancy complications in population studies. These associations do not predict an individual outcome. [1] [2]

BV is not classified as an STI, yet sexual activity influences risk and recurrence. CDC notes associations with a new sexual partner, multiple partners, lack of condom use and douching. BV can also occur in people who do not identify their symptoms with recent sexual activity. The biology is more complex than a single organism passing from one person to another. [1]

BV is not a hygiene failure

BV does not mean that the vagina was dirty or that someone failed to wash. Internal washing and douching are not solutions and may increase risk. A fishy odour comes from chemical compounds produced within the altered environment, not from poor personal character. [1] [2] [3]

Likewise, a diagnosis cannot establish when the change began, who “gave” it to whom, or whether a partner was unfaithful. Those conclusions go beyond the evidence.

What are the symptoms of BV?

BV may cause a thin, fairly uniform white or grey discharge and a noticeable fishy odour, sometimes more apparent after sex or during menstruation. Many people with BV report no symptoms. Itching, marked soreness and pain are less typical and should broaden the differential diagnosis. [1] [2] [3] [4]

Possible features include:

• a new or persistent fishy vaginal odour
• thin or watery-looking discharge that seems different from your baseline
• a relatively uniform white, off-white or grey appearance
• mild irritation in some people
• no noticeable symptom at all

The absence of odour does not exclude BV. The presence of odour does not prove it. Semen, menstruation, sweating, a retained tampon, trichomoniasis and other changes can alter scent. Colour descriptions also vary with lighting, underwear and the person observing them.

BV versus yeast infection versus an STI

Marked vulval swelling, cracks, intense itch or thick discharge may point more toward candidiasis, but they still do not prove it. Bleeding after sex, pelvic pain or urinary symptoms may suggest cervicitis, an STI, pelvic inflammatory disease or another condition. Mixed infections can occur. [4] [5]

Conditions that can resemble BV

A clinician may consider:

• vulvovaginal candidiasis
• trichomoniasis
• chlamydial or gonococcal cervicitis
• irritant or allergic contact dermatitis
• retained tampon or another foreign body
• low-estrogen tissue change, including genitourinary syndrome of menopause
• less common inflammatory vaginal conditions
• pelvic inflammatory disease when pelvic pain, cervical tenderness, fever or other signs are present

Repeatedly treating “BV” based only on smell can therefore miss another diagnosis or expose you to unnecessary medicine.

Do your symptoms need assessment?

Use this decision framework rather than trying to identify BV from one clue.

Situation 1: First episode or uncertain pattern

Consider assessment before treatment. A first episode of fishy odour or changed discharge may be BV, but yeast, an STI, irritation and retained material require different care. This is especially relevant when you have used several products, because irritation can blur the pattern.

Situation 2: Symptoms after a previous confirmed BV diagnosis

Contact a clinician if the symptoms recur. A familiar pattern raises suspicion but does not guarantee the same diagnosis. Guidelines allow retreatment approaches, yet a clinician should consider whether testing, a different regimen or a recurrence strategy is appropriate. [1] [6]

Situation 3: Possible STI exposure

BV testing is not a substitute for STI testing. If you have a new partner, a partner diagnosed with an STI, unprotected exposure, bleeding after sex, pelvic pain or concern about infection, request an exposure-appropriate assessment. A generic “vaginal swab” does not automatically test for every STI. [4] [5]

Situation 4: Pregnancy

Contact the clinician or maternity service responsible for your pregnancy if you have symptoms. Symptomatic pregnant patients should be assessed and treated with pregnancy-appropriate options. Watery leakage, bleeding, significant pain, fever or feeling unwell needs prompt pregnancy-specific advice. [1] [2]

Situation 5: No symptoms, incidental result or home-test change

Do not automatically self-treat. Routine treatment of asymptomatic BV is not recommended for every person, and indications differ by pregnancy, procedure, test type and guideline. Ask the clinician who ordered or interpreted the test what the result means in your context. [1] [6]

How is BV diagnosed?

BV can be diagnosed with a combination of clinical findings, microscopy with Gram staining, or certain validated molecular tests. A fishy smell, discharge appearance or pH result alone is insufficient. The available method varies by healthcare setting, and no single service necessarily offers every test. [1] [4] [5] [6]

Amsel criteria

The traditional clinical approach uses four findings:

1. thin, homogeneous discharge
2. vaginal pH above 4.5
3. a characteristic amine odour after adding potassium hydroxide, often called the whiff test
4. clue cells seen on microscopy

A diagnosis is generally supported when at least three of the four are present. Amsel criteria combine observations rather than relying on one symptom. The performance depends on sampling and the person conducting the assessment. [1]

Gram stain and Nugent scoring

A laboratory can stain a vaginal sample and assess bacterial morphotypes under a microscope. The Nugent score classifies the pattern according to the relative presence of Lactobacillus-like and other bacterial forms. CDC describes Gram stain with Nugent scoring as a reference laboratory method. It describes a community pattern, not a single “BV germ.” [1]

Molecular tests, including NAATs

Several nucleic acid amplification tests, or NAATs, detect combinations of bacterial targets associated with BV and sometimes Lactobacillus markers. Some panels also test for Candida or trichomoniasis. They can be useful for symptomatic patients, but brand, specimen type and validation matter. A molecular panel is not a universal microbiome analysis, and a positive organism signal must be interpreted using the test’s approved algorithm and clinical context. [1]

CDC notes that BV NAAT accuracy is not well defined for asymptomatic women and recommends using them among symptomatic women. Availability differs between services. Some settings use clinician-collected vaginal samples; some validated assays permit self-collected vaginal samples after instructions. That does not mean every self-swab or home kit is equivalent. [1]

What an assessment may involve

A respectful assessment usually starts with conversation:

• what changed and when
• odour, discharge, itch, burning, pain or bleeding
• pregnancy possibility or current pregnancy
• recent antibiotics and vaginal products
• previous BV and how it was diagnosed
• sexual exposures relevant to STI testing
• medicines, allergies and other health conditions

An examination or sample may be offered based on the situation. You should be told what is proposed and why. You can ask to pause or stop an examination, discuss a smaller speculum where appropriate, or ask whether a validated self-collected sample is an option. Comfort varies, so no one should promise that an internal examination is painless.

Why home pH is not a BV test

BV often raises vaginal pH, but so can trichomoniasis, blood, semen and lower-estrogen states. Yeast infection often does not raise pH. A home strip can therefore suggest that something has changed without identifying what. It cannot rule out an STI, confirm BV or select an antibiotic. [1] [4] [5]

How is BV treated?

Major guidelines recommend antibiotics for symptomatic BV. Common first-line BV treatment options include oral metronidazole, intravaginal metronidazole gel and intravaginal clindamycin cream. The choice should be clinician-led because pregnancy, allergy, interactions, side effects, route preference, previous response and local guidance matter. [1] [6]

The table describes guideline options at a high level. It is not a dosing instruction or a recommendation for you personally.

What treatment is trying to do

Treatment aims to resolve symptoms and reduce short-term infectious complications. It does not guarantee that the vaginal community will remain unchanged forever. Recurrence after treatment is common and is not proof that you took the medicine incorrectly, that a partner was unfaithful or that your hygiene failed. [1] [7]

During treatment

Use the prescribed medicine exactly as directed and complete the course unless the prescriber tells you otherwise. Ask what to do if a dose is missed, vomiting occurs, symptoms worsen or side effects are difficult. Do not add a douche, vaginal deodorant, herb, boric acid or probiotic as an improvised second treatment.

CDC advises refraining from sexual activity or using condoms consistently during the treatment regimen. Product choice matters because clindamycin cream is oil-based and may weaken latex barrier products; labels for particular products give the relevant interval. [1]

Metronidazole and alcohol: updated wording

Older advice often states that alcohol with metronidazole causes a dangerous disulfiram-like reaction. The current CDC BV guideline says evidence for that interaction is unconvincing and that abstaining from alcohol during metronidazole therapy is unnecessary. That is a correction to a blanket rule, not permission to ignore your own prescription label, pharmacist or prescriber. Alcohol may worsen nausea, dizziness or other side effects, and local product information may differ. [1]

Do not transfer this statement to tinidazole or another medicine. Each product has its own labeling, interactions and evidence. If instructions conflict, ask the prescriber or pharmacist who can review the exact medicine and your health history.

What if symptoms do not improve?

Do not simply repeat treatment indefinitely. Return for assessment if symptoms persist, worsen or recur soon after treatment. Possible explanations include recurrent BV, an incorrect initial diagnosis, mixed infection, reinfection with an STI, poor tolerance or adherence, resistance-related concerns, a foreign body, or a noninfectious condition. [1] [4] [6] [7]

No routine test of cure is required for every nonpregnant person whose symptoms resolve, but follow-up decisions vary with symptoms, pregnancy, recurrent disease and the original test. Follow the clinician’s plan.

BV in pregnancy and breastfeeding

Symptomatic BV during pregnancy should be evaluated and treated with a pregnancy-appropriate regimen. BV has been associated with adverse pregnancy outcomes, but screening and treating every asymptomatic pregnant person is not a universal recommendation. Pregnancy changes the balance of benefits, evidence and medicine selection. [1] [2]

Contact the healthcare professional or maternity service responsible for your pregnancy rather than choosing a leftover or over-the-counter product. Metronidazole and clindamycin have pregnancy data and appear in guidelines, but route and regimen still need individual selection. Allergy, gestational context, symptoms, other medicines and local protocols matter. [1]

Do not use intravaginal boric acid during pregnancy. Safety data are insufficient, and guidance advises avoidance. Never swallow boric acid. [13]

Breastfeeding is not identical to pregnancy. Medicine decisions may depend on the exact drug, dose, route, infant age, prematurity and current reference information. Ask a prescriber or pharmacist rather than assuming that a pregnancy statement answers a breastfeeding question.

Watery leakage, vaginal bleeding, significant pelvic or abdominal pain, fever or feeling very unwell in pregnancy needs prompt pregnancy-specific advice. A home pH test cannot safely distinguish BV from amniotic-fluid leakage.

Why does BV come back?

BV recurrence is common because treatment may reduce BV-associated bacteria without permanently changing the ecological and sexual factors that help the dysbiotic community re-form. Biofilm, bacterial exchange between partners, menstruation, douching and individual microbiome patterns may contribute, but no single explanation fits everyone. [1] [7]

A recurrence can occur after a correctly completed course. Recurrence can be exhausting, but it is not a personal failure.

First recurrence

CDC states that using a different recommended regimen can be considered, although retreatment with the same recommended regimen is acceptable after a first recurrence. The choice belongs with a clinician who can review the original diagnosis, adherence, side effects, pregnancy status and whether another cause should be tested. [1]

Multiple recurrences

For people with several recurrences after completing recommended treatment, CDC describes suppressive approaches involving intravaginal metronidazole over a longer period. It also describes a multi-step option that includes an oral nitroimidazole, then intravaginal boric acid, then suppressive metronidazole gel. Evidence and individual suitability vary, benefit may not continue after suppression stops, and these approaches require clinician oversight. [1]

This article deliberately does not provide a self-start dose schedule. A recurrence plan must account for pregnancy, medicine interactions, product availability, diagnostic certainty and the possibility of another infection.

A useful recurrence review

Bring a simple record to an appointment:

• date each episode began and whether BV was laboratory- or clinically confirmed
• symptoms and how they differed from yeast or irritation
• treatment name, route, completion and side effects
• how long symptoms stayed away
• relation to menstruation or sexual activity, without treating timing as proof of cause
• douching, fragranced products or intravaginal practices
• new partners or STI exposure concerns
• pregnancy possibility and contraception or barrier use relevant to medicine choice

The goal is to confirm the pattern and choose an evidence-based strategy.

Boric acid, probiotics and live biotherapeutics

Boric acid

Boric acid is sometimes included in clinician-managed regimens for selected recurrent BV cases. It is not a routine first-line treatment, a “natural reset” or a harmless product to try whenever odour returns. Evidence for BV relates to particular multi-step strategies, not casual or indefinite use. [1] [7] [13]

Safety rules are essential:

• Never swallow boric acid. It is toxic if ingested.
• Do not use it during pregnancy or when pregnancy may be possible without medical review. Current evidence is insufficient to establish pregnancy safety. [13]
• Keep it securely away from children, pets and anyone who could mistake a capsule for an oral medicine.
• Use only a product and regimen selected by a qualified clinician for a defined indication.
• Stop and seek advice for significant irritation, bleeding, worsening pain or systemic symptoms.

Do not make boric acid at home or put unlabeled powder into capsules. Do not combine it with other intravaginal products unless the treating clinician has reviewed the plan.

Retail probiotics

Probiotic products differ by species, strain, dose, route, storage and manufacturing quality. A study of one strain cannot validate a different oral capsule, yoghurt or vaginal product. Systematic reviews find a mixed and heterogeneous evidence base, so probiotics should not replace recommended antibiotic treatment or evaluation of recurrent symptoms. [10]

The label “probiotic” is too broad to support a class-wide promise; evidence must match the exact product and outcome.

Live biotherapeutics

LACTIN-V is an investigational live biotherapeutic containing a specific Lactobacillus crispatus strain. Trials have reported encouraging recurrence outcomes after antibiotic treatment, including follow-up work, but these findings are product-specific. They do not establish that retail probiotics are equivalent. Regulatory status and local availability must be verified at the time of care rather than assumed. [11] [12]

For now, describe live biotherapeutics as promising and evolving, not standard universal therapy.

Should a partner be treated for BV?

There is no single BV partner treatment rule that fits every case. CDC’s 2021 guideline does not recommend routine treatment of sex partners. A 2025 randomized trial and 2026 New York State guidance support discussing concurrent treatment of an ongoing male partner for recurrent symptomatic BV in selected circumstances. This is an evolving shared decision, not a universal instruction. [1] [8] [9]

What changed in 2025 and 2026?

The 2025 trial studied monogamous couples in which the woman had symptomatic BV and a male partner received combined oral and topical antimicrobial treatment at the same time as the woman’s treatment. The trial found lower recurrence in the partner-treatment group and was stopped early because of the observed benefit. Its results challenge the older conclusion that male-partner treatment does not help. [9]

The result does not answer every question. It involved a defined regimen, a particular population and ongoing male partners. It does not show that any antibiotic, any partner regimen or treatment of all current and past partners will prevent recurrence. Adherence, adverse effects, antimicrobial stewardship and local prescribing rules still matter.

New York State’s 2026 guidance now recommends discussing partner treatment and offers an approach for ongoing male partners, particularly in recurrent symptomatic BV. Other jurisdictions may not yet have adopted the same recommendation, and CDC’s publicly available 2021 guideline retains its routine non-treatment stance. [1] [8]

A practical partner decision

Ask a clinician about concurrent partner treatment when all of the following are relevant:

• your BV is symptomatic and has been appropriately diagnosed
• recurrences have followed recommended treatment
• you have an ongoing male partner
• both partners can be assessed for contraindications, adherence and local prescribing requirements
• you understand that benefit is supported by newer evidence but is not guaranteed

For female partners, evidence is less developed. A partner with discharge, odour, irritation, pain or other symptoms should have their own assessment rather than taking someone else’s medicine. BV partner management must also stay separate from STI partner management, where notification and treatment rules depend on the specific infection.

A BV diagnosis does not prove infidelity; partner discussion should remain factual and non-accusatory.

What can you do yourself?

Self-care can reduce irritation and avoid practices associated with BV, but it cannot guarantee that BV will never recur.

Helpful steps

• Do not douche or insert cleansing, deodorizing, herbal or “detox” products. [1] [2] [3]
• Wash the external vulva gently. Internal washing is unnecessary.
• Use prescribed treatment as directed and discuss side effects rather than silently stopping.
• Check the label for vaginal clindamycin products if you rely on latex condoms or diaphragms. [1]
• Use condoms consistently during treatment if that is the plan discussed with your clinician. [1]
• Seek exposure-appropriate STI testing when indicated. BV testing does not cover every STI.
• Keep a recurrence record so repeated episodes can be confirmed rather than guessed.

What has not been proven as a reliable cure

Avoid treating BV with yoghurt, garlic, tea tree oil, vinegar, steam, antiseptics, fragranced washes or a home pH “balancing” product. These can irritate tissue, obscure symptoms or delay appropriate treatment. Diet, hydration and underwear changes are not substitutes for diagnosis or antibiotics.

A home pH strip can neither confirm a cure nor establish recurrence. Commercial microbiome tests may report organisms without providing a validated diagnosis or treatment pathway.

Myths and facts about BV

When should you seek urgent care?

Do not assume that pelvic pain, bleeding or severe illness is “just BV.”

Call Saudi ambulance 997 or go to the nearest emergency department for collapse, fainting with severe symptoms, heavy bleeding, severe or rapidly worsening abdominal or pelvic pain, breathing difficulty, confusion or another life-threatening concern. [14]

Seek urgent same-day medical advice through an appropriate service for fever with pelvic pain, vomiting with inability to keep fluids down, marked illness, rapidly worsening genital swelling or pain, or pregnancy with bleeding, watery leakage, significant pain or fever. These features can point to pregnancy complications, pelvic inflammatory disease or another condition needing prompt assessment.

Arrange prompt non-emergency assessment for persistent or recurrent odour or discharge, symptoms after STI exposure, bleeding after sex, urinary pain, or any new persistent watery, bloody or offensive discharge after menopause. A prepubertal child with discharge, bleeding, pain, foul odour, suspected injury, a possible foreign body or safeguarding concern needs pediatric assessment.

Frequently asked questions

The bottom line

BV is a treatable vaginal dysbiosis, not a verdict about cleanliness, sexual behavior or fidelity. Thin discharge and fishy odour may fit the pattern, but they cannot confirm it. A sound plan starts with the right diagnosis, then uses a clinician-selected treatment that accounts for pregnancy, medicines, preferences and local guidance, consistent with official patient guidance from the Saudi Ministry of Health. [15]

If BV returns, the next step is not endless self-treatment. Reconfirm the pattern and discuss recurrence options, strict boric-acid safety, the limits of retail probiotics and whether newer partner-treatment evidence applies to your situation. Guidance is moving, especially around ongoing male partners, so this part deserves current clinical review.

If the change is persistent, recurrent or uncomfortable, or associated with bleeding, pain, urinary symptoms or pregnancy, consider a general gynecological assessment. Emergencies belong with 997 or the nearest emergency department.

References

1. Centers for Disease Control and Prevention. Bacterial Vaginosis, STI Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/bv.htm
2. World Health Organization. Bacterial vaginosis. https://www.who.int/news-room/fact-sheets/detail/bacterial-vaginosis
3. NHS. Bacterial vaginosis. https://www.nhs.uk/conditions/bacterial-vaginosis/
4. International Union against Sexually Transmitted Infections Europe. 2023 European guideline for the management of vaginal discharge. https://iusti.org/wp-content/uploads/2023/04/IUSTI-vaginal-discharge-guidelines_2023.pdf
5. American College of Obstetricians and Gynecologists. Vaginitis. https://www.acog.org/womens-health/faqs/vaginitis
6. International Society for the Study of Vulvovaginal Disease. Recommendations for the Diagnosis and Treatment of Vaginitis. 2023. https://www.issvd.org/application/files/4916/7897/2719/ISSVD_recommendations_for_the_diagnosis_and_treatment_of_vaginitis.pdf
7. Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10423565/
8. New York State Department of Health AIDS Institute. Partner Treatment to Prevent Recurrent Bacterial Vaginosis. Updated 2026. https://www.hivguidelines.org/guideline/sti-bv/
9. Infectious Diseases Society of America. Will Treating Male Partners Prevent Bacterial Vaginosis Recurrence? 2025 evidence review. https://www.idsociety.org/science-speaks-blog/2025/will-treating-male-partners-prevent-bacterial-vaginosis-recurrence/
10. Probiotics for the prevention of vaginal infections: a systematic review. 2024. PubMed. https://pubmed.ncbi.nlm.nih.gov/39135840/
11. Sustained effect of LACTIN-V on genital immunology and recurrent bacterial vaginosis. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9188188/
12. LACTIN-V live biotherapeutic trial record. PubMed. https://pubmed.ncbi.nlm.nih.gov/40194532/
13. Mittelstaedt R, et al. Data on safety of intravaginal boric acid use in pregnant and non-pregnant women: a narrative review. https://pmc.ncbi.nlm.nih.gov/articles/PMC10100571/
14. Saudi Arabia Unified National Platform. Emergency Contact Guide. https://my.gov.sa/en/emergency-contact
15. Saudi Ministry of Health. Bacterial Vaginosis. Published 18 September 2023. https://www.moh.gov.sa/en/healthawareness/educationalcontent/wh/pages/0011.aspx